A Review On Comprehensive Study Of Cytokine Inhibitors On Treatment Of Psoriasis

  • Sowmiya B
  • Narayanan. J
  • Chitra V
Keywords: psoriasis, pathogenesis, cytokine inhibitor, clinical data, efficacy and safety of psoriasis treatment

Abstract

Psoriasis, a chronic inflammatory skin condition caused by immune system malfunction, is treated with cytokine inhibitors. The pathophysiology of psoriasis highlights the functions of key cytokines essential to the inflammatory processes of the condition, including TNF-α, Interleukin-17, and Interleukin-12/23. Clinical information is provided on a range of biologic medicines, with an emphasis on their safety, efficacy, and ability to alleviate psoriasis symptoms. These medications include secukinumab, bimekizumab, guselkumab, and deucravacitinib. More recent therapies, such as the topical cream tapinarof, are also examined, along with information on ongoing research and development of biologics targeting specific cytokine pathways. These targeted medicines have improved treatment outcomes, decreased disease severity, and enhanced patients' quality of life, as evidenced by clinical studies and real-world data.

Author Biographies

Sowmiya B

Department of Pharmacology, SRM College of Pharmacy, SRM Institute of Science and Technology, Kattankulathur, Chennai, Tamil Nadu

Narayanan. J

Department of Pharmacology, SRM College of Pharmacy, SRM Institute of Science and Technology, Kattankulathur, Chennai, Tamil Nadu

Chitra V

Department of Pharmacology, SRM College of Pharmacy, SRM Institute of Science and Technology, Kattankulathur, Chennai, Tamil Nadu

References

1. Fulmali S, Thurka S, Sultana R, Padmaja P: A comparative study on efficacy of treatment regimens with Calcipotriol/Betamethasone Dipropionate Vs Calcipotriol ointments in Plaque type Psoriasis patients at Tertiary Care Hospital, Telangana. Asian Journal of Pharmacy and Pharmacology. 2022, 8:58–65. 10.31024/ajpp.2022.8.2.5
2. Abdallah HB, Johansen C, Iversen L: Key Signaling Pathways in Psoriasis: Recent Insights from Antipsoriatic Therapeutics. Psoriasis Targets and Therapy. 2021, Volume 11:83–97. 10.2147/ptt.s294173
3. Loite U, Raam L, Reimann E, et al.: The Expression Pattern of Genes Related to Melanogenesis and Endogenous Opioids in Psoriasis. International Journal of Molecular Sciences. 2021, 22:13056. 10.3390/ijms222313056
4. Georgescu S-R, Tampa M, Caruntu C, et al.: Advances in Understanding the Immunological Pathways in Psoriasis. International Journal of Molecular Sciences. 2019, 20:739. 10.3390/ijms20030739
5. Rahman M, Alam K, Ahmad MZ, et al.: Classical to Current Approach for Treatment of Psoriasis: A Review. Endocrine Metabolic & Immune Disorders - Drug Targets. 2012, 12:287–302. 10.2174/187153012802002901
6. Wrone-Smith T, Nickoloff BJ: Dermal injection of immunocytes induces psoriasis. Journal of Clinical Investigation. 1996, 98:1878–87. 10.1172/jci118989
7. Guo J, Zhang H, Lin W, Lu L, Su J, Chen X: Signaling pathways and targeted therapies for psoriasis. Signal Transduction and Targeted Therapy. 2023, 8:. 10.1038/s41392-023-01655-6
8. Singh R, Koppu S, Perche PO, Feldman SR: The Cytokine Mediated Molecular Pathophysiology of Psoriasis and Its Clinical Implications. International Journal of Molecular Sciences. 2021, 22:12793. 10.3390/ijms222312793
9. Armstrong AW, Gooderham M, Warren RB, et al.: Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial. Journal of the American Academy of Dermatology. 2023, 88:29–39. 10.1016/j.jaad.2022.07.002
10. Albanesi C, Madonna S, Gisondi P, Girolomoni G: The Interplay Between Keratinocytes and Immune Cells in the Pathogenesis of Psoriasis. Frontiers in Immunology. 2018, 9:. 10.3389/fimmu.2018.01549
11. Mease PJ, Deodhar AA, Van Der Heijde D, et al.: Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis. Annals of the Rheumatic Diseases. 2022, 81:815–22. 10.1136/annrheumdis-2021-221664
12. Morand E, Pike M, Merrill JT, et al.: Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double‐Blind, Placebo‐Controlled Trial. Arthritis & Rheumatology. 2022, 75:242–52. 10.1002/art.42391
13. Thaçi D, Strober B, Gordon KB, et al.: Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial. Dermatology and Therapy. 2022, 12:495–510. 10.1007/s13555-021-00649-y
14. Langley RG, Elewski BE, Lebwohl M, et al.: Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials. New England Journal of Medicine. 2014, 371:326–38. 10.1056/nejmoa1314258
15. Deodhar A, Mease PJ, McInnes IB, et al.: Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data. Arthritis Research & Therapy. 2019, 21: 10.1186/s13075-019-1882-2
16. Papp KA, Langley RG, Sigurgeirsson B, et al.: Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study. British Journal of Dermatology. 2013, 168:412–21. 10.1111/bjd.12110
17. Gordon KB, Langley RG, Warren RB, et al.: Bimekizumab Safety in Patients With Moderate to Severe Plaque Psoriasis. JAMA Dermatology. 2022, 158:735. 10.1001/jamadermatol.2022.1185
18. Mcinnes IB, Asahina A, Coates LC, et al.: Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL). The Lancet. 2023, 401:25–37. 10.1016/s0140-6736(22)02302-9
19. Coates LC, McInnes IB, Merola JF, et al.: Safety and Efficacy of Bimekizumab in Patients With Active Psoriatic Arthritis: Three‐Year Results From a Phase IIb Randomized Controlled Trial and Its Open‐Label Extension Study. Arthritis & Rheumatology. 2022, 74:1959–70. 10.1002/art.42280
20. Elgaard CDB, Iversen L, Hjuler KF: Guselkumab, tildrakizumab, and risankizumab in a real-world setting: drug survival and effectiveness in the treatment of psoriasis and psoriatic arthritis. Journal of Dermatological Treatment. 2022, 34:. 10.1080/09546634.2022.2133531
21. Ruggiero A, Megna M, Fabbrocini G, Ocampo-Garza SS: Anti-IL23 biologic therapies in the treatment of psoriasis: real-world experience versus clinical trials data. Immunologic Research. 2023, 71:328–55. 10.1007/s12026-022-09356-y
22. Zhang C, Yan K, Diao Q, et al.: A multicenter, randomized, double-blinded, placebo-controlled, dose-ranging study evaluating the efficacy and safety of vunakizumab in patients with moderate-to-severe plaque psoriasis. Journal of the American Academy of Dermatology. 2022, 87:95–102. 10.1016/j.jaad.2022.01.005
23. Nogueira S, Rodrigues MA, Vender R, Torres T: Tapinarof for the treatment of psoriasis. Dermatologic Therapy. 2022, 35:. 10.1111/dth.15931
24. Singh R, Balogh EA, Feldman SR: Update on IL-17 Inhibitors for Psoriasis. Current Dermatology Reports. 2020, 9:339–52. 10.1007/s13671-020-00322-1
25. Azevedo A, Torres T: Clinical Efficacy and Safety of Ixekizumab for Treatment of Psoriasis. Actas Dermo-Sifiliográficas. 2017, 108:305–14. 10.1016/j.ad.2016.09.021
Published
2024-07-21
How to Cite
Sowmiya B, Narayanan. J, & Chitra V. (2024). A Review On Comprehensive Study Of Cytokine Inhibitors On Treatment Of Psoriasis. Revista Electronica De Veterinaria, 25(1), 2445 -2462. https://doi.org/10.69980/redvet.v25i1.1252
Section
Articles